Patent Application Titled "Bispecific Antibody Against Cd3 And Cd20 In Combination Therapy For Treating Diffuse Large B-Cell Lymphoma" Published Online (USPTO 20240301078).

A patent application has been published online for a method of treating diffuse large B-cell lymphoma (DLBCL) using a combination therapy. DLBCL is a common type of non-Hodgkin lymphoma, and current treatments have limited effectiveness for high-risk patients. The method involves administering a bispecific antibody along with a standard treatment regimen in 21-day cycles. Different dosing schedules are provided depending on the specific treatment regimen, and the treatment continues until certain response criteria are met or until disease progression or unacceptable toxicity occurs. The method is applicable to different types of DLBCL and patients with specific prognostic scores. [Extracted from the article]